evenfolio

Healthcare · NSE: INDGN

Indegene

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
662.40−0.57%

Q2 FY27 earnings call · Guided by management

Call held 30 Oct 2026 · Read the filing on NSEFiling

19​%Quarterly EBITDA margin · Q4 FY27Prabhu · p. 8
90–95​bpsPBT margin impact · coming quartersPrabhu · p. 8
2–3​quartersTime to return to $25 million-plus cohortPrabhu · p. 8
15​%Revenue growth threshold for second tranche · calendar year 2026Gupta · p. 7
M.Cap
₹15,962Cr
P/E
38.8×
1Y return
+29.92%
From 52W high
−2.2%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue1,122804+39.6%1,063+5.6%
EBITDA186141+32.1%174+6.6%
EBITDA margin16.6%17.5%-93 bps16.4%+16 bps
PBTProfit before tax147133+10.7%153-3.5%
Net profit112102+10.0%116-3.4%
EPS (₹)4.644.23+9.7%4.81-3.5%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY26 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.

Guidance

EBITDA margin · FY2719%keptQuarterly EBITDA margin of 19% plus targeted by Q4 FY27; outlook unchanged
Margin · FY2790-95 bpsLower amortisation and higher yields expected to lift PBT by up to 90-95 bps

Goal restated: organic growth rate better than FY26; no formal guidance

Manish Gupta · Chairman and Chief Executive Officer · p. 9
“While we do not provide formal guidance, I want to restate 2 goals we had set for ourselves and discussed with you all. First, organic growth rate better than FY26 with our biggest relationships and our newer ones moving forward together as we did this quarter.”

This year expected organically stronger than last year; H2 stronger than H1

Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 15
“We believe this year should be organically a stronger year than last year, and H2 would be stronger than H1.”

Quarterly EBITDA margins expected back in historical range by Q4

Manish Gupta · Chairman and Chief Executive Officer · p. 9
“The second one was our quarterly EBITDA margins back in our historical range by Q4, as Suhas mentioned, as our go-to-market investments and successes in deal wins get into full-scale execution reflecting in the revenue through this period.”

More figures from the call

Company · Demand
400​US$ billionRevenue facing patent expiry · next decade
“At the same time, more than $400 billion worth of revenue faces patent expiry over the next decade. For us, that translates into demand.”
Manish Gupta · Chairman and Chief Executive Officerp. 4

In short

  1. 01Management kept its path to quarterly EBITDA margins of 19% plus by Q4 FY27.
  2. 02Q2 revenue was INR11,223 million, up 39.5% year-on-year; EBITDA margin was 16.7%.
  3. 03Management restated the goal of organic growth better than FY26, and said H2 should be stronger than H1.
  4. 04The wage hike cut margins by about 150 bps; lower treasury yields hit PBT by about 90 bps.
  5. 05PBT is expected to gain up to 90 to 95 bps from lower amortisation and higher yields.
  6. 069 deal wins above about $1 million in annual value, including one above $5 million and two of $3-5 million.
  7. 07Revenue from the $10 million outcome-based contract is expected to peak in Q4.
  8. 08BioPharm earn-out expected close to maximum; the amount is already provided for.

Order book

9 deal wins of about $1 million ACV, incl. one $5 million-plus and two $3-5 million

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“9 deal wins with annual contract values about $1 million, including 3 large deals, one in the $5 million-plus range and 2 in the $3 million to $5 million range.”

Enterprise Commercial: Largest win: top 5 customer mandate to migrate content platform outside the U.S.

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“In the largest new deal win of this quarter, we won a mandate from our existing top 5 customer to migrate the content platform in new geographies outside the U.S.”

Enterprise Commercial: Largest deal work started in Q3; ramp-up likely to impact Q4 and beyond

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“While the work commenced in Q3, the ramp-up will likely impact Q4 and beyond.”

Enterprise Commercial: Top 20 pharma consulting work became a global content factory mandate

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“A top 20 pharma company had bought us in for a change management consulting engagement. Last quarter, we described it then as a sub-million start with a real room to grow. One quarter later, it has become a mandate to set up a global content factory across Commercial and Medical content for the company's international business.”

Enterprise Commercial: Top 30 pharma deal to manage global digital content, replacing a large incumbent

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“Finally, the last large deal win is from a top 30 global pharma company to manage their global digital content where we are replacing a large incumbent.”

Segments

Enterprise Commercial: Revenue mix: Enterprise Commercial about 71%, Enterprise Medical 25%, Others 4%

Suhas Prabhu · Chief Financial Officer · p. 8
“The business mix was steady with Enterprise Commercial contributing about 71% of our revenue and Enterprise Medical 25%, followed by Others at 4%.”

North America: Geography mix: North America 74%, Europe 23%, rest of world 3%

Suhas Prabhu · Chief Financial Officer · p. 8
“By geography, North America continued to be the highest contributor, accounting for 74%, followed by Europe at 23% and the rest of the world, 3%.”

Tectonic: Tectonic run rate $1.7 million a quarter; contracts above $2 million a quarter

Suhas Prabhu · Chief Financial Officer · Q&A · p. 10
“Tectonic has grown from a run rate of about $1 million a quarter to $1.7 million this quarter. And the contracts, as we mentioned, have actually crossed a level of more than $2 million a quarter as we look ahead.”

Enterprise Commercial: Commercial may grow faster than Medical for the next few quarters

Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 14
“But for the next few quarters, we might see higher growth rates in Commercial.”

Enterprise Medical: Good number of Medical deals in the pipeline

Suhas Prabhu · Chief Financial Officer · Q&A · p. 14
“But we continue to see a good number of deals in the pipeline in Medical as well.”

Demand

Revenue from largest customer expected to return to an upward path

Suhas Prabhu · Chief Financial Officer · p. 8
“And as execution catches up, we expect revenue from this client to return to an upward path.”

Top 5 accounts grew 9.2% and top 20 about 6.7% sequentially in INR

Manish Gupta · Chairman and Chief Executive Officer · p. 4
“Our top 5 accounts grew 9.2% sequentially in INR terms, and our top 20 accounts grew about 6.7%.”

107 active clients, 31 more than a year ago; $1 million-plus clients rose to 59

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“We now serve 107 active clients, 31 more than a year ago. Clients contributing over $1 million a year rose to 59, up from 54 last quarter.”

Clients above $10 million now number 13, one more than last quarter

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“Clients above $10 million, now numbers 13, one more than last quarter.”

All but one Q2 win was output or outcome-based; share expected to keep rising

Suhas Prabhu · Chief Financial Officer · Q&A · p. 13
“most of our wins in the current quarter, Prolin, have been output or outcome-based rather than FTE-based contracts but for one. And that gives us confidence that this number would keep trending upwards.”

Margins and costs

Margin growth in H2 likely to outpace revenue growth by exit of Q4

Suhas Prabhu · Chief Financial Officer · p. 9
“And as all of this play out, margin growth in H2 is likely to outpace the revenue growth as we exit quarter 4.”

PAT margin expected to expand faster than EBITDA margin in coming quarters

Suhas Prabhu · Chief Financial Officer · p. 8
“This would help our PAT margin expand faster than our EBITDA margin in the coming quarters.”

Amortisation charge to reduce from Q3

Suhas Prabhu · Chief Financial Officer · p. 8
“Amortization charge will reduce in quarter 3 and beyond.”

Wage hike cut margins by about 150 bps, largely offset by productivity and forex

Suhas Prabhu · Chief Financial Officer · p. 7
“And this year, the wage hike impacted margins by about 150 basis points. Improved productivity and favorable exchange rates have largely offset this impact.”

Interest income down 44% sequentially from INR237 million to INR134 million

Suhas Prabhu · Chief Financial Officer · p. 7
“However, interest income was down 44% sequentially from INR237 million to INR134 million.”

Debt and working capital

Treasury yields expected to rise; portfolio shifting to held-to-maturity instruments

Suhas Prabhu · Chief Financial Officer · p. 8
“We anticipate yields to increase with the higher interest rates prevailing combined with a conscious shift in the investment portfolio towards a higher allocation to held-to-maturity instruments, which reduce volatility.”

Net DSO up 2 days to 69 days; cash and investments INR13,896 million

Suhas Prabhu · Chief Financial Officer · p. 8
“The DSO net of unearned and unbilled revenue was slightly higher at 69 days, up 2 days. And cash and investments stood strong at INR13,896 million.”

Receivables and unbilled expected to return to normal in Q3 and Q4

Suhas Prabhu · Chief Financial Officer · Q&A · p. 10
“But we believe going into quarter 3 and quarter 4, we would see the AR and the unbilled more importantly, coming back to what we see normally.”

Acquisitions and new business

BioPharm back-office transition finished by end of February, ahead of March plan

Manish Gupta · Chairman and Chief Executive Officer · p. 6
“We had planned to transition finance, HR, IT and legal, and close out the seller’s transition services by the end of March. We finished that by the end of February with no disruption to client engagements and strong retention.”

BioPharm cost synergies about $1.5 million a year, reinvested in sales team

Manish Gupta · Chairman and Chief Executive Officer · p. 6
“On cost synergies, we have realized around $1.5 million in annual savings, and we reinvested these savings in growth, most visibly by expanding BioPharm's go-to-market team from 3 to 9 people.”

Full BioPharm earn-out amount already provided for in balance sheet

Manish Gupta · Chairman and Chief Executive Officer · p. 7
“Just a caveat, we have already provided for this entire amount in our balance sheet.”

BioPharm data and targeting used in some of the largest pursuits in pipeline

Manish Gupta · Chairman and Chief Executive Officer · p. 7
“We are including BioPharm capabilities in existing and new enterprise omnichannel engagements. Its data and targeting capabilities are now giving us an edge in some of our largest pursuits, which sit in our pipeline right now.”

One-offs

Mutual fund NAV markdown cut yields; hit PBT by about 90 bps and PAT by about 70 bps

Suhas Prabhu · Chief Financial Officer · p. 7
“While the invested funds largely remained constant quarter-on-quarter, the markdown in our mutual fund portfolio NAVs due to the increase in interest rates towards the end of the quarter compressed the near-term yields. The quarter-on-quarter impact of lower yields impacted PBT by about 90 basis points and PAT by about 70 basis points.”

Risks

Largest customer revenue eased as Tectonic engagements ramp up more gradually

Suhas Prabhu · Chief Financial Officer · p. 8
“Revenue from our largest customer slightly eased this quarter as the Tectonic engagements that we signed with them are ramping up more gradually, though the scope we contracted keeps expanding.”

Tectonic ramp-up with largest customer remains slow

Manish Gupta · Chairman and Chief Executive Officer · p. 5
“While Tectonic wins continue to accumulate with the largest customer, the ramp-up in this case remains slow.”

Frontier AI labs not seen as a threat; partnership team set up in U.S. and India

Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 10
“We don't see that as a threat to our model of working. We have put a dedicated partnership team in place in the U.S. and India and are partnering with multiple players in the broader tech ecosystem.”

IT companies rarely seen as competitors; main rivals are agencies and CROs

Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 13
“In all transparency, we don't see IT too much, at least in the kind of deals we compete on.”

Largest client's slow ramp put down to central vs local brand team change management

Manish Gupta · Chairman and Chief Executive Officer · Q&A · p. 11
“Getting those organizational dynamics right in these very, very large companies takes time, given it is a new area.”

Other

Q2 revenue INR11,223 million, up 39.5% year-on-year and 5.6% sequentially

Manish Gupta · Chairman and Chief Executive Officer · p. 4
“Revenues came in at INR11,223 million, up 39.5% year-on-year and 5.6% sequentially.”

Q2 revenue US$117.5 million, up 27.5% year-on-year and 4.4% sequentially in dollars

Suhas Prabhu · Chief Financial Officer · p. 7
“Revenue for the second quarter was INR11,223 million or US$117.5 million. In dollar terms, that is a strong growth of 27.5% year-on-year and 4.4% sequentially.”

Q2 EBITDA INR1,873 million, up 32% year-on-year, margin 16.7%

Suhas Prabhu · Chief Financial Officer · p. 7
“EBITDA came in at INR1,873 million, up 32% year-on-year at a margin of 16.7%.”

PBT INR1,474 million; PAT up 10% to INR1,123 million; tax rate 23.8%

Suhas Prabhu · Chief Financial Officer · p. 8
“Profit before tax was INR1,474 million, with the effective tax rate steady at 23.8%. Profit after tax was up 10% from a year ago at INR1,123 million or 10% of revenue.”

Largest customer 7.8% of revenue; top 10 make up 49%

Suhas Prabhu · Chief Financial Officer · p. 8
“Our largest customer today represents 7.8% of revenue and our top 10 together make up 49%.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools